<?xml version="1.0" encoding="UTF-8"?>
<ref id="R56">
 <label>56.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sharman</surname>
    <given-names>JP</given-names>
   </name>
   <name>
    <surname>Egyed</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Jurczak</surname>
    <given-names>W</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial</article-title>. 
  <source>
   <italic toggle="yes">Lancet.</italic>
  </source>
  <year>2020</year>;
  <volume>395</volume>:
  <fpage>1278</fpage>â€“
  <lpage>1291</lpage>.
  <pub-id pub-id-type="pmid">32305093</pub-id>
 </mixed-citation>
</ref>
